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Identity 
Other names: FRA, FRA1, fra-1 




Fra-1 (Fosl-1) is a basic leucine zipper (bZIP) 
transcription factor and a member of Fos family of 
proteins (Cohen and Curran, 1988). The Fra-1 gene 
spans about 8.31 kb including four exons and is located 
on chromosome 11q13. It contains two regulatory 
elements, an upstream 5'-flanking region and an 
intragenic sequence, that are known to regulate its 
transcriptional induction (Verde et al., 2007). Two 
critical elements of the promoter, the upstream TPA 
response element (TRE) and the serum response 
element (SRE), are required for Fra-1 transcriptional 
induction in response to external stimuli, such as 
mitogens and cytokines (Adiseshaiah et al., 2003; 
Adiseshaiah et al., 2005). The intragenic regulatory 
element containing the TRE/TRE-like elements also 
contribute to Fra-1 induction (Bergers et al., 2005). 
Transcription 
Fra-1 transcription is strongly inducible by mitogens 
and inflammatory cytokines as well by a wide variety 
of environmental toxicants,  
carcinogens, and pathogens. In contrast to the early 
activation of c-Jun and c-Fos (which peaks at 15-30 
min), the induction of Fra-1 by various mitogenic and 
stressful stimuli peaks at 90-180 min, and this delay d 
induction is postulated to play important role in 
modulating the transcriptional response initiated by the 
AP-1 complex composed of Jun/c-Fos dimers. The Fra-
1 promoter region contains a c-Fos-like serum respon e 
element (SRE), which is constitutively occupied by the
serum response factor (SRF) and the ternary complex 
factor, Elk1. Recruitment of c-Jun to the upstream TRE 
and the presence of downstream SRE as well as the 
activating transcription factor (ATF) site are essential 
for Fra-1 induction by mitogenic and cytokine stimuli 
(Adiseshaiah et al., 2007). Sp1 family members also 
regulate Fra-1 transcription (Adiseshaiah et al., 2005).  
Other studies have shown that cis-elements, such as 
TRE and E boxes, located in the intragenic region also
contribute to Fra-1 transcription (Bergers et al., 1995, 
Casalino et al., 2003,).  
Histone modifications, such as the phosphorylation of 
Histone 3 by PIM1 on the nucleasome at the MYC 
binding sites, regulate the transcriptional activation of 
Fra-1 (Zippo et al., 2007). 
 In addition to transcriptional induction, ERK- 
dependent phosphorylation has been shown to play a 
key role in the protein stability and DNA binding 
activity of Fra-1 (Basbous et al., 2007, Young et al., 
2002). 
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Transcriptional regulation of Fra-1 (Fosl-1): MAPK signaling activates transcriptional factors binding at the human Fra-1 promoter. 
Binding of Fra-1 and c-Jun to TRE sites of first intron regulates Fra-1 transcription. TRE - TPA response element, SRE - Serum response 
element, SRF - serum response factor, ATF - activating transcription factor binding site. 
 
A schematic diagram showing the modular structure of Fra-1 (1-271 AA). DBD -DNA binding domain, LZD - leucine-zipper domain, 
N - amino terminus, C - carboxyl terminus. P1 - Thr 231, P2 - Ser252, P3 - Ser265. In this, ERK mediated phosphorylation of serine 
residues 252 and 265 requires for the stabilization of Fra-1 in certain tumor cell lines (Basbous et al., 2007). 
 
Pseudogene 
One pseudo gene is identified, the FOS-like antigen 
pseudogene, FOSL1P1 (NCBI, HGNC ID: 44055). 
Protein 
Description 
Fra-1 (Fosl-1) protein encodes for 271 amino acids 
with an expected molecular weight of 29.4 kDa. 
However, in immunoblot analysis of cellular extracts 
isolated from cells stimulated with growth factors or 
from cancer cells, Fra-1 exhibits multiple forms 
ranging from 30-40 kDa. The appearance of these 
multiple forms is mainly attributed to post-translational 
modification (e.g., phosphorylation) of this protein. 
Human and mouse Fra-1 exhibits 6 and 1 splice 
variants, respectively, and both exhibit one unspliced 
form. These different transcripts encode proteins with 
different functional domains. The functional 
significance of these alternatively spliced variants of 
Fra-1 for both in physiology and pathological processes 
remains unclear. 
Expression 
The expression of Fra-1 is high in smooth muscle cels, 
bronchial epithelial cells (trachea), and the pancreas, 
but its expression is low in other tissues, such as the 
brain and prostate. 
Localisation 
Fra-1 (Fosl-1) contains a nuclear localization signal and 
is predominantly found in the nucleus. However, Fra-1 
antigen is observed in the cytoplasm under certain 
conditions, such as elevated levels of oxidative str s  
(Burch et al., 2004) and in cancerous tissues (Song et 
al., 2006). Furthermore, a distinct cytoplasmic location 
of Fra-1 has been noted in non-small-cell lung cancer 
(Ma et al., 2009). Nuclear and cytoplasmic expression 
of Fra-1 is markedly elevated in human adenomas, 
adenocarcinomas and neuroendocrine carcinomas 
(Zhang et al., 2005). 
Function 
After dimerization, mainly with the Jun or ATF family 
of proteins, Fra-1 binds to the TPA response element 
(TRE, or AP-1 site) and regulates gene expression in a 
context-dependent manner (Cohen et al., 1989). Fra-1 
plays important roles in various biological processes, 
including inflammation, transformation, proliferation, 
and metastasis. Increased expression levels of Fra-1 is 
detectable in breast, lung, brain, colon and prostate 
cancers and its knockdown affects cancer cell 
progression (see below). 
Homology 
The Fra-1 gene is conserved in chimpanzee, dog, cow, 
mouse, rat, and Zebra fish. 
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Mutations 
Note 
No genetic mutations leading to activation or 
inactivation of this transcription factor in human 
disease development and in malignancies have been yet 
documented. Recently, the presence of SNPs was 
demonstrated in human Fra-1 (FOSL-1) gene, and these 
SNPs were shown to be associated with a decreased 




Analysis of samples from thyroid cancer patients ha
shown an increase in Fra-1 protein expression in 
thyroid nodules (Chiappetta et al., 2000). Induction of 
Fra-1 expression has also been observed in human 
thyroid cancer cell lines (Battista et al., 1998).  
Inhibition of Fra-1 prevents the retrovirally induced 
neoplastic transformation of rat thyroid cells (Vallone 
et al., 1997). In thyroid cancer cells, Fra-1 binds to the 
cyclin A promoter and regulates its expression during 
cell-cycle progression (Casalino et al., 2007). 
Non-small-cell lung cancer (NSCLC) 
Note 
Expression of AP-1 family proteins, and particularly 
Fra-1 has been detected in NSCLC cell lines (Risse-
Hackl et al., 1998). Decreased levels of Fra-1 protein 
expression have been noted in the tumor tissue of non 
small cell lung cancer patients (Ma et al., 2009), and 
these decreased levels have been positively correlated 
with progression of tumor stage and worsening 
prognosis. Ectopic expression of Fra-1 in lung 
adenocarcinoma cells induces cancer. Interestingly, it 
has been reported that a DNA vaccine specific to Fra-1 
prevents pulmonary cancer metastasis in syngeneic 
mice (Luo et al., 2005). 
Breast cancer 
Note 
Increased expression of Fra-1 was observed in human 
breast cancer cells (Philips et al., 1998). Several studies 
have shown its involvement in cancer cell proliferation, 
motility and invasiveness (Bamberger et al., 1999; 
Belguise et al., 2005; Logullo et al., 2011). An increase 
in nuclear or cytoplasmic localization of Fra-1 has been 
considered as a marker of progression of breast cancer 
(Song et al., 2006, Chiappetta et al., 2007). Knockd wn 
of Fra-1 in tumor associated macrophages with small 
interfering RNA has been found to significantly 
suppress the invasion, angiogenesis and metastasis of 
breast cancer tumor cells (Luo et al., 2010). Likewis , 
knockdown of Fra-1 in estrogen- resistant MCF-7 cells 
significantly affected their growth and enhanced their 
susceptibility to cell death in response to estrogen 
treatment (Pennanen et al., 2011). An increased 
accumulation of Fra-1 protein in estrogen-negative 
breast cancer cells is mediated through PKCθ pathway 
(Belguise et al., 2012).  
A mouse Fra-1 targeted DNA vaccine has been found 
to be effective in protection against breast cancer in 
mice (Luo et al., 2003). Low level of miRNA-34 has 
been correlated with an elevated level of Fra-1 
expression in breast cancer tissues and cell lines, but 
ectopic miRNA-34 expression causes a down-
regulation of Fra-1 levels and inhibits breast cancer cell 
progression (Yang et al., 2012). In a different study, 
Fra-1 overexpression was shown to increase the 
chemosensitive of breast cancer stem cells, suggestin  
Fra-1 can be considered as a prognostic responsive 
marker in breast cancer therapy (Lu et al., 2012). 
Bladder cancer 
Note 
An increased level of Fra-1 expression is found in 
bladder tumor and cancer cell lines. Fra-1, via the
transcriptional induction of the receptor tyrosine kinase 




Fra-1 and its dimeric partner, c-Jun, are up-regulated in 
human colorectal tumors (Zhang et al., 2005; Wang et 
al., 2002). In colon carcinoma cells, the basal induction 
and stabilization of Fra-1 has been shown to be 
regulated by ERK activity, and knockdown of Fra-1 
suppresses colon cancer cell polarization and 
progression (Vial and Marshall, 2003). A potential role 
for Fra-1 in the regulation of vimentin during Ha-RAS-
induced epithelial-to- mesenchymal transition and 
migration has been documented (Andreolas et al., 
2008). By upregulating miR-34a, p53 indirectly down 
regulates Fra-1 mRNA and protein expression in colon 
cancer cells and inhibits cell migration and invasion 
(Wu et al., 2012). 
Prostate cancer 
Note 
Akt signaling contributes to Fra-1 induction in the 
prostate cancer cells, mainly at the transcription level 
(Tiwari et al., 2003). An abnormal activation of Fra-1 
has been linked to elevated expression levels of IL-6, 
which promote prostate cancer cell progression and 
resistance to chemotherapeutic agents (Zerbini et al., 
2003). 
Esophageal squamous cell carcinoma 
(ESCC) 
Note 
Immunoreactive analysis of two different ESCC cell 
lines (HKESC-1 and HKESC-2) derived from ESCC 
patients has demonstrated Fra-1 expression in thesecell 
line (Hu et al., 2001). An elevated level of Fra-1 
expression is associated with poor prognosis of ESCC. 
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Furthermore, Fra-1 knockdown in ESCC cell lines 
decreases tumor cell progression and invasion (Usui et 
al., 2012). 
Nasopharyngeal carcinoma (NPC) 
Note 
Expression profiling of nasopharyngeal carcinoma and
normal cells has revealed elevated expression levels of 
Fra-1 in NPC cancer cells (Fung et al., 2000). Fra-1 has 
been shown to play an important role in controlling 
latent membrane protein 2A (LMP2A)-induced NPC 
epithelial cell motility and invasiveness (Lan et al., 
2012). Either inhibition of Fra-1 induction or 
suppression of ERK1 and ERK2 activation will block 
the LMP2A-induced MMP-9 expression required for 
cancer cell progression. 
Glioma 
Note 
Ectopic Fra-1 expression in malignant glioma cells 
leads to phenotypic changes associated with 
invasiveness and tumorigenicity (Debinski and Gibo, 
2005). In contrast, knock down of Fra-1 in high-grade 
glioma (HGG) cells alters the morphology, reduces 
both anchorage-independence and tumorigenic 
potential (Debinski and Gibo, 2011). In rat C6 glioma 
cells, Fra-1 overexpression suppresses their 
proliferation rate and tumorogenic potential and 
promotes cellular apoptosis (Shirsat and Shaikh, 2003). 
Head and neck squamous cell 
carcinoma (HNSCC) 
Note 
Analysis of the tumor samples from patients with head 
and neck squamous cell carcinomas (HNSCC) has 
shown an increase in Fra-1 mRNA expression when 
compared to matched adjacent mucosa samples.  
Furthermore, tumor tissue staining for Fra-1 in tumor 
tissues is intensely more reactive immunoreactive than 
that of adjacent normal tissue (Mangone et al., 2005). 
Fibrosis 
Note 
Fra-1 transgenic mice have been shown to be prone to 
developing biliary hepatic fibrosis, and Fra-1 has been 
associated with ductular proliferation and infiltration of 
inflammatory cells (Kireva et al., 2011). On the other 
hand, it negatively regulates pulmonary fibrosis 
(Rajasekaran et al., 2012). Genetic disruption of Fra-1 
causes increased levels of inflammation, collagen 
accumulation, and profibrotic and fibrotic gene 
expression following bleomycin treatment when 
compared to wild-type Fra-1. 
Osteopetrosis 
Note 
Genetic disruption of Fos leads to osteopetrosis in mice 
(Matsuo et al., 2000). However, over expression of Fra-
1 rescues this phenotype in c-Fos mutant mice. Rankl, 
an osteoclast differentiation factor, has been report d to 
induce Fra-1 expression in a c-Fos-dependent manner, 
suggesting the involvement of c-Fos-RANKL-Fra-1 
signaling in osteoclast differentiation.  
It has also been reported that overexpression of Fra-1 in 
mice increases bone mass up to 5-fold compared to 
wild-type mice (Roschger et al., 2004). 
Acute lung injury and Sepsis 
Note 
Increased expression of Fra-1 has been reported in lung 
epithelial cell of acute respiratory syndrome patients 
(Fudala et al., 2011).  
Mice lacking Fra-1 show decreased levels of acute lung
injury and inflammation as well as increased survival 
following endotoxin (LPS) treatment when compared 
to their wild-type counterparts (Vaz et al., 2012); this 
improvement was associated with diminished and 
increased levels of NF-kB and c-Jun/AP-1 binding, 
respectively.  
In agreement with this result, mice overexpressing Fra-
1 were shown in another study to have enhanced 
susceptibility to endotoxin-induced death (Takada et 
al., 2011). 
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